1 Study Coverage
1.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) & (US$ Million) Introduction
1.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Outlook 2017 VS 2022 VS 2028
1.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size for the Year 2017-2028
1.2.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size for the Year 2017-2028
1.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.3.1 The Market Share of United States Non-Alcoholic Steatohepatitis (NASH) Drugs in Global, 2017 VS 2022 VS 2028
1.3.2 The Growth Rate of Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Dynamics
1.4.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Industry Trends
1.4.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Drivers
1.4.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Challenges
1.4.4 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Restraints
1.5 Study Objectives
1.6 Years Considered
2 Non-Alcoholic Steatohepatitis (NASH) Drugs by Type
2.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Segment by Type
2.1.1 Vitamin E & Pioglitazone
2.1.2 Obeticholic Acid (OCA)
2.1.3 Elafibranor
2.1.4 Selonsertib & Cenicriviroc
2.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2017, 2022 & 2028)
2.3 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2017-2028)
2.4 United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2017, 2022 & 2028)
2.5 United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2017-2028)
3 Non-Alcoholic Steatohepatitis (NASH) Drugs by Application
3.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Segment by Application
3.1.1 Hospital Pharmacy
3.1.2 Online Provider
3.1.3 Retail Pharmacy
3.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2017, 2022 & 2028)
3.3 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2017-2028)
3.4 United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2017, 2022 & 2028)
3.5 United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2017-2028)
4 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Competitor Landscape by Company
4.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Company
4.1.1 Top Global Non-Alcoholic Steatohepatitis (NASH) Drugs Companies Ranked by Revenue (2021)
4.1.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Player (2017-2022)
4.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Concentration Ratio (CR)
4.2.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Companies of Non-Alcoholic Steatohepatitis (NASH) Drugs in 2021
4.2.3 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Headquarters, Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) & (US$ Million) Type
4.3.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Headquarters and Area Served
4.3.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Companies Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022) & (US$ Million) Type
4.3.3 Date of International Companies Enter into Non-Alcoholic Steatohepatitis (NASH) Drugs Market
4.4 Companies Mergers & Acquisitions, Expansion Plans
4.5 United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Company
4.5.1 Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players in United States, Ranked by Revenue (2021)
4.5.2 United States Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Players (2020, 2021 & 2022)
5 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region
5.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (2017-2028)
5.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region: 2017-2022
5.2.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (2023-2028)
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth 2017-2028
6.1.2 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth 2017-2028
6.3.2 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth 2017-2028
6.4.2 Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 AstraZeneca
7.1.1 AstraZeneca Company Details
7.1.2 AstraZeneca Business Overview
7.1.3 AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
7.1.4 AstraZeneca Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
7.1.5 AstraZeneca Recent Development
7.2 Conatus Pharmaceuticals
7.2.1 Conatus Pharmaceuticals Company Details
7.2.2 Conatus Pharmaceuticals Business Overview
7.2.3 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
7.2.4 Conatus Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
7.2.5 Conatus Pharmaceuticals Recent Development
7.3 Enzo Biochem
7.3.1 Enzo Biochem Company Details
7.3.2 Enzo Biochem Business Overview
7.3.3 Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
7.3.4 Enzo Biochem Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
7.3.5 Enzo Biochem Recent Development
7.4 Galmed Pharmaceuticals
7.4.1 Galmed Pharmaceuticals Company Details
7.4.2 Galmed Pharmaceuticals Business Overview
7.4.3 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
7.4.4 Galmed Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
7.4.5 Galmed Pharmaceuticals Recent Development
7.5 Genfit
7.5.1 Genfit Company Details
7.5.2 Genfit Business Overview
7.5.3 Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
7.5.4 Genfit Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
7.5.5 Genfit Recent Development
7.6 Gilead
7.6.1 Gilead Company Details
7.6.2 Gilead Business Overview
7.6.3 Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
7.6.4 Gilead Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
7.6.5 Gilead Recent Development
7.7 Horizon Pharma
7.7.1 Horizon Pharma Company Details
7.7.2 Horizon Pharma Business Overview
7.7.3 Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
7.7.4 Horizon Pharma Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
7.7.5 Horizon Pharma Recent Development
7.8 Immuron
7.8.1 Immuron Company Details
7.8.2 Immuron Business Overview
7.8.3 Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
7.8.4 Immuron Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
7.8.5 Immuron Recent Development
7.9 Intercept Pharmaceuticals
7.9.1 Intercept Pharmaceuticals Company Details
7.9.2 Intercept Pharmaceuticals Business Overview
7.9.3 Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
7.9.4 Intercept Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
7.9.5 Intercept Pharmaceuticals Recent Development
7.10 Novo Nordisk
7.10.1 Novo Nordisk Company Details
7.10.2 Novo Nordisk Business Overview
7.10.3 Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction
7.10.4 Novo Nordisk Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2017-2022)
7.10.5 Novo Nordisk Recent Development
8 Research Findings and Conclusion
9 Appendix
9.1 Research Methodology
9.1.1 Methodology/Research Approach
9.1.2 Data Source
9.2 Author Details
9.3 Disclaimer
